SCHEMBL95920

SCHEMBL95920

[CH2]c1ccc(C(=O)N2CCN(C3CCOCC3)CC2)cc1

nearest known ligand 0.62

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
L3MBTL3 Q96JM7 11/20 0.62
L3MBTL1 Q9Y468 9/20 0.62
HRH3 Q9Y5N1 5/20 0.61
MBTD1 Q05BQ5 5/20 0.55
TP53BP1 Q12888 2/20 0.55
L3MBTL4 Q8NA19 2/20 0.55
KDM4E B2RXH2 2/20 0.51
POLB P06746 1/20 0.51
ALDH1A1 P00352 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL94754 0.89 L3MBTL3 (0.79) L3MBTL3L3MBTL1HRH3MBTD1TP53BP1
SCHEMBL96590 0.87 L3MBTL3 (0.75) L3MBTL3L3MBTL1HRH3MBTD1TP53BP1
SCHEMBL12237827 0.86 L3MBTL3 (0.62) L3MBTL3L3MBTL1HRH3MBTD1TP53BP1
SCHEMBL10293553 0.85 KDM4E (0.69) L3MBTL3L3MBTL1HRH3KDM4EPOLB
SCHEMBL423599 0.81 PHGDH (0.69) L3MBTL1KDM4EPOLBALDH1A1
SCHEMBL95490 0.79 L3MBTL3 (0.85) L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4
Bavisant SCHEMBL522603 0.76 HRH3 (1.00) L3MBTL3L3MBTL1HRH3MBTD1
SCHEMBL5048005 0.75 L3MBTL3 (0.50) L3MBTL3L3MBTL1HRH3MBTD1ALDH1A1
SCHEMBL1169820 0.75 L3MBTL3 (0.66) L3MBTL3L3MBTL1HRH3MBTD1TP53BP1
Bavisant SCHEMBL521755 0.75 HRH3 (1.00) L3MBTL3L3MBTL1HRH3MBTD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362252-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-01-29 US disclosed
EP-1797082-B1 CARBOSTYRIL COMPOUND OTSUKA PHARMA CO LTD (JP) 2012-08-29 EP disclosed
EP-2426128-A1 Carbostyril compound Otsuka Pharmaceutical Co., Limited (JP) 2012-03-07 EP disclosed
US-20100261705-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. 2010-10-14 US disclosed
US-7777038-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-08-17 US disclosed
US-20090326008-A1 NF-kappa B Inhibitor OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-12-31 US disclosed
EP-2043644-A1 NF- B INHIBITOR Otsuka Pharmaceutical Co., Ltd. (JP) 2009-04-08 EP disclosed
WO-2008010601-A1 NF- ϰB INHIBITOR OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2008-01-24 WO disclosed
US-20070179173-A1 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-02 US disclosed
EP-1797082-A1 CARBOSTYRIL COMPOUND Otsuka Pharmaceutical Company, Limited (JP) 2007-06-20 EP disclosed
WO-2006035954-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326008-A1 NF-kappa B Inhibitor NFKBIA, NFKB2, IKBKB L3MBTL3 1998/4885L3MBTL1 1099/4885HRH3 1957/4885
US-20070179173-A1 Carbostyril compound GTF2F1, F3, GTF2F2 L3MBTL3 889/4885L3MBTL1 262/4885HRH3 303/4885
US-20100261705-A1 CARBOSTYRIL COMPOUND GTF2F1, F3, GTF2F2 L3MBTL3 889/4885L3MBTL1 262/4885HRH3 303/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.